

FORM PTO-1390
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

50.US3.PCT

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/807506

INTERNATIONAL APPLICATION NO.

PCT/IB99/01730

INTERNATIONAL FILING DATE

October 12, 1999

PRIORITY DATE CLAIMED

October 13, 1998

TITLE OF INVENTION

GENES, PROTEINS AND BIALLELIC MARKERS RELATED TO CENTRAL NERVOUS SYSTEM DISEASE

APPLICANT(S) FOR DO/EO/US

Marta BLUMENFELD, Lydie BOUGUELERET, Ilya CHUMAKOV, Daniel COHEN, Laurent ESSIUX


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☒ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

U.S. APPLICATION NO. (37 CFR 2.101) 097807506		INTERNATIONAL APPLICATION NO. PCT/IB99/01730		ATTORNEY'S DOCKET NUMBER																										
21. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY																										
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	860.00																									
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>24 - 20 =</td> <td>4</td> <td>x \$18.00</td> <td>\$ 64.00</td> </tr> <tr> <td>Independent claims</td> <td>8 - 3 =</td> <td>5</td> <td>x \$80.00</td> <td>\$ 400.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$270.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 1,724.00</td> </tr> </tbody> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	24 - 20 =	4	x \$18.00	\$ 64.00	Independent claims	8 - 3 =	5	x \$80.00	\$ 400.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00	TOTAL OF ABOVE CALCULATIONS =				\$ 1,724.00	\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																										
Total claims	24 - 20 =	4	x \$18.00	\$ 64.00																										
Independent claims	8 - 3 =	5	x \$80.00	\$ 400.00																										
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$270.00																										
TOTAL OF ABOVE CALCULATIONS =				\$ 1,724.00																										
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	0.00																									
SUBTOTAL =				\$	1,724.00																									
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0.00																									
TOTAL NATIONAL FEE =				\$	1,724.00																									
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	0.00																									
TOTAL FEES ENCLOSED =				\$	1,724.00																									
<div style="display: flex; justify-content: space-between;"> Amount to be refunded: \$ </div>																														
<div style="display: flex; justify-content: space-between;"> charged: \$ </div>																														
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,724.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>50-1181</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-1181</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																														
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.																														
SEND ALL CORRESPONDENCE TO: <div style="display: flex; justify-content: space-between;"> <div style="width: 60%;"> GENSET CORP. 10665 Sorrento Valley Road San Diego, CA 92121-1609 Telephone: 858/597-2600 Facsimile: 858/597-2601 </div> <div style="width: 35%; text-align: center;"> SIGNATURE John Lucas, Ph.D., J.D. NAME 43,373 REGISTRATION NUMBER </div> </div>																														
Express Mail Label #EL821903793US																														



097 807506
JCO Rec'd PCT/PTO 13 APR 2001

G E N S E T

Direct Dial: (858) 597-2610
E-Mail: john.lucas@genxy.com

April 13, 2001

Express Mail Label No. EL821903793US

Assistant Commissioner for Patents
Washington, D.C. 20231

RE: United States Designated/Elected Office
U.S. Patent Application For: GENES, PROTEINS AND BIALLELIC MARKERS
RELATED TO CENTRAL NERVOUS SYSTEM DISEASE
Inventors: MARTA BLUMENFELD, LYDIE BOUGUELERET, ILYA CHUMAKOV,
DANIEL COHEN, LAURENT ESSIUX
Our Ref.: 50.US3.PCT

Dear Sir:

Submitted herewith, please find the above-identified application for filing with the United States Patent and Trademark Office. This application claims priority on PCT/IB99/01730, filed October 12, 1999. The following documents are transmitted herewith:

	<u>Quantity</u>
1) Transmittal Letter to the United States Designated/Elected Office (DO/ES/US) Concerning a Filing under 35 U.S.C. 371 (in duplicate)	2 pages
2) Application Data Sheet	4 pages
3) Preliminary Amendment	15 pages
4) Two Copies of the Sequence Listing on CD-ROM	2 CD-ROMs
5) Check in the amount of \$1,724.00	
6) Return Postcard	

The Commissioner is hereby authorized to charge any additional fees, or credit any overpayment in the processing of these documents to our Deposit Account No. 50-1181.

Very truly yours,

GENSET CORPORATION

John Lucas, Ph.D., J.D.
Reg. No. 43,373

JL/cmm
Enclosures
cc: Helene Sarrascca (w/encls.)

Certificate of Mailing under 37 CFR 1.10

Express Mail Label No.: EL821903793US Date of Deposit: April 13, 2001
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the Date of Deposit shown above, postage prepaid and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Signature
AARON J. SCALIA
Typed or Printed Name of Person Signing Certificate